With AMVUTTRA
for the treatment of the polyneuropathy of hATTR amyloidosis in adults, your patients may1
FEEL MORE IN THE MOMENT1-3
AMVUTTRA® (vutrisiran) is the only treatment that can reverse the polyneuropathy manifestations of hATTR amyloidosis with 4 doses per year1,2,4-6,a
Patient portrayal.
At 9 months in a randomized, open-label study, patients treated with AMVUTTRA were compared with an external placebo group and demonstrated1,2:
Rapid knockdown
of TTR as early as 3 weeks1,2
Improvement in neuropathy impairment, as measured by mNIS+71,2
Improvement in quality of life, as measured by Norfolk QoL-DN1,2
Improvement in gait speed, as measured by 10MWT1
aAdministered once every 3 months.
10MWT=10-meter walk test; mNIS+7=modified Neuropathy Impairment Score + 7; Norfolk QoL-DN=Norfolk Quality of Life-Diabetic Neuropathy.
More than 1,000 patients are receiving treatment with AMVUTTRA in the US, making it the #1-prescribed treatment for the polyneuropathy of hATTR amyloidosis in adults.7
Explore the pivotal study design and the efficacy and safety of AMVUTTRA
Learn how to administer AMVUTTRA
Find out how to get your patients started with AMVUTTRA